Pivekimab, referred to as IBAT®, represents the innovative genetically engineered monoclonal immunoglobulin engineered to selectively interact with or neutralize interleukin-6, the critical molecule implicated to the https://ztndz.com/story28498741/pivekimab-the-deep-investigation-into-the-engineered-targeted-antibody